dcct landmark trial

26
Grethel Fatima Castañeda, MD With Hannah Urbanozo-Corpuz, MD, FPCP, FPSEDM

Upload: itrmcmedicine

Post on 14-Feb-2017

67 views

Category:

Health & Medicine


0 download

TRANSCRIPT

Page 1: DCCT Landmark Trial

Grethel Fatima Castañeda, MD With

Hannah Urbanozo-Corpuz, MD, FPCP, FPSEDM

Page 2: DCCT Landmark Trial

9 February 2017

Journal Club

GRETHEL FATIMA CASTAÑEDA, MD WITH

HANNAH URBANOZO-CORPUZ, MD, FPCP, FPSEDM

Page 3: DCCT Landmark Trial

What is the DCCT?

◦ Diabetes Control and Complications Trial (DCCT)

◦ major clinical study conducted from 1983 to 1993

◦ National Institute of Diabetes and Digestive and Kidney Diseases

◦ The study compared the effects of standard control of blood glucose versus

intensive control on the complications of diabetes.

Page 4: DCCT Landmark Trial

Diabetes Control and Complications Trial

Conventional Treatment

◦ 1-2 insulin injections per day

Intensive Treatment

◦ > 3 insulin injections per day

◦ Insulin pump

Page 5: DCCT Landmark Trial

DCCT (1983-1993) ◦ Study Design: parallel-arm, randomized clinical trial

◦ Study Population: 1441 IDDM, 13-39yrs old ◦ primary prevention cohort (726 no retinopathy)

◦  secondary intervention cohort (715 mild retinopathy)

◦ Intervention: (unmasked)

◦  Intensive arm: insulin pump or ≥ 3 daily insulin injections

◦ Conventional arm: 1-2 insulin injections

Page 6: DCCT Landmark Trial

ELIGIBILITY CRITERIA PRIMARY PREVENTION SECONDARY PREVENTION

MAJOR CRITERIA Insulin dependence

13-39 y/o

No hypertension, hypercholesterolemia or severe diabetic complications

IDDM for 1-5 years IDDM for 1-15 years

No retinopathy Mild to moderate retinopathy

Urine albumin <40mg in 24 hrs Urine albumin <200mg in 24 hrs

Page 7: DCCT Landmark Trial
Page 8: DCCT Landmark Trial

CLINICAL QUESTIONS

Primary prevention

◦ Will an intensive treatment program prevent the development of retinopathy in patients with no retinopathy?

Secondary intervention

◦ Will such an intervention affect the progression of early retinopathy to more advanced forms of retinopathy?

Page 9: DCCT Landmark Trial
Page 10: DCCT Landmark Trial

RESULTS

◦ 99% competed the study

◦ 11 died

◦ 32 inactive

◦ 8 lost to ff up

◦ 95 women, originally on conventional treatment transferred

to intensive treatment during pregnancy

Page 11: DCCT Landmark Trial
Page 12: DCCT Landmark Trial

How did intensive treatment affect diabetic eye disease? ◦ All DCCT participants were monitored for diabetic retinopathy

◦ Study results showed that intensive therapy reduced the risk for

developing retinopathy by 76 percent.

◦ In participants who had some eye damage at the beginning of

the study, intensive management slowed the progression of the

disease by 54 percent.

Page 13: DCCT Landmark Trial
Page 14: DCCT Landmark Trial
Page 15: DCCT Landmark Trial

How did intensive treatment affect diabetic kidney disease? ◦ Participants in the DCCT were tested to assess the development of diabetic kidney disease, or nephropathy.

◦ Findings showed that intensive treatment prevented the development and slowed the progression of diabetic kidney disease by 56 percent.

Page 16: DCCT Landmark Trial
Page 17: DCCT Landmark Trial
Page 18: DCCT Landmark Trial

How did intensive treatment affect diabetic nerve disease?

◦ Participants in the DCCT were examined to detect the development of nerve damage, or diabetic neuropathy.

◦ Study results showed the risk of nerve damage was reduced by 60 percent in people on intensive treatment.

Page 19: DCCT Landmark Trial
Page 20: DCCT Landmark Trial

intensive

conventional

Abnormal

Page 21: DCCT Landmark Trial

How did intensive treatment affect diabetes-related cardiovascular disease?

◦ Detection macrovascular events were unlikely due to short time frame.

◦ Reduced development of hypercholesterolemia (LDL >160mg/dl) by 34%

Page 22: DCCT Landmark Trial

What are the risks of intensive treatment? ◦ HYPOGLYCEMIA ◦ 3x increase both in the intensive and conventional treatment groups ◦ 62 px in intensive vs 19 px in conventional treatment ◦ Seizure due to hypoglycemia - 16 px in intensive vs 5 px in conventional treatment ◦ 2 – vehicular accident ◦ Hospitalization due to hypoglycemia - 54 px in intensive vs 36 px in conventional treatment

Page 23: DCCT Landmark Trial

What are the risks of intensive treatment? ◦ WEIGHT GAIN ◦ Body weight > 120% of IBW ◦ Increased by 33% in intensive treatment

◦ DKA ◦ 1.8 episodes in conventional treatment ◦ 2 episodes in intensive treatment

Page 24: DCCT Landmark Trial

SUMMARY and RECOMMENDATIONS

◦ Intensive therapy delays the progression of clinically important retinopathy.

◦ There is transient worsening of retinopathy with intensive therapy which

occurred mainly on the first year of therapy.

◦ Intensive therapy reduced the risk of albuminuria and microalbuminuria.

◦ Whether the decrease in albuminuria and microalbuminuria result in the

decrease of renal insufficiency, follow-up of the entire cohort must be

done.

Page 25: DCCT Landmark Trial

SUMMARY and RECOMMENDATIONS

◦ The ability of intensive therapy to reduce development of neuropathy

suggests that neuropathy may be preventable.

◦ Whether intensive therapy may reduce macrovascular complications

requires further investigation.

◦ Benefits of reducing hyperglycemia are extended to NIDDM patients

Page 26: DCCT Landmark Trial

•  IDDM patient are better treated with closely monitored intensive therapy.

•  Keeping blood glucose levels as close to normal as possible slows the onset and progression of the eye, kidney, and nerve damage caused by diabetes.

•  The study demonstrated that any sustained lowering of blood glucose helps, even if the person has a history of poor control.

LEARNING POINTS